Banner
Browse by multiple fields below

Download csv Download xlsx
PDX ID Sample ID Patient Id Sample Site Sample Source Age Sample Collected PSA at diagnosis (ng/mL) Gleason Score Primary Gleason Score Secondary Gleason Score Grade Group Tumour Grade D'Amico Risk Classification Primary Tumour Volume (cc) Treatment Prior to Specimen Collection PDX Host Type PDX Graft Site Current PDX Generation Average PDX Generation Time (days ± SEM) Tumour preparation2 Pubmed ID
374M Cx 374M 374 Liver Biopsy 70-74 NA 0.0 ADT Castrate Subcutaneous 21 (13*) 56 ± 4 Tumor solid 34413304
382M 382M 175/382 Liver Biopsy 70-74 NA 0.0 ADT, docetaxel, cabazitaxel, abiraterone Testosterone supplemented Renal 11 41 ± 4 Tumor solid 34413304
387.38A 387.38A 387 Para-tracheal lymph node Autopsy 60-64 NA 0.0 ADT, docetaxel, cabazitaxel, enzalutamide, lutetium PSMA, pembrolizumab Testosterone supplemented Subcutaneous 19 57 ± 3 Tumor solid 34413304
387.38A Cx 387.38A 387 Para-tracheal lymph node Autopsy 60-64 NA 0.0 ADT, docetaxel, cabazitaxel, enzalutamide, lutetium PSMA, pembrolizumab Castrate Subcutaneous 12 (4*) 201 ± 35 Tumor solid 34413304
394M 394M 394 Liver Biopsy 75-79 NA 0.0 ADT, docetaxel, cabazitaxel, enzalutamide, navelbine Testosterone supplemented Subcutaneous 9 96 ± 11 Tumor solid 34413304
394M Cx 394M 394 Liver Biopsy 75-79 NA 0.0 ADT, docetaxel, cabazitaxel, enzalutamide, navelbine Castrate Subcutaneous 9 (4*) 132 ± 23 Tumor solid 34413304
395M 395M 395 Suprapubic mass Surgery 65-69 NA 0.0 None Testosterone supplemented Subcutaneous 8 158 ± 14 Tumor solid 34413304
407M 407M 407 Liver Biopsy 75-79 NA 0.0 ADT, docetaxel, abiraterone, enzalutamide Testosterone supplemented Subcutaneous 9 73 ± 6 Tumor solid 34413304